星期四 - 12月 15, 2016

孟山都股東同意拜耳併購案
併購里程碑,共創農業產業的全球領導地位/預計2017年底完成交易

【聖路易】2016年12月13日─孟山都公司宣布,12月13日舉行的股東特別會議中,股東核准孟山都與拜耳公司的獨資型態子公司合併。根據併購協議,孟山都股東將在併購完成時,獲得每股128美元的現金。

孟山都董事長兼執行長Hugh Grant說,「我們非常高興得到股東強烈的支持。這是一個很重要的里程碑,我們努力結合兩家足以匹配的公司,傳遞我們對於未來農業的共同遠景。藉由結合我們的專業和資源打造的這個共同遠景,甚至可以攜手嘉惠全世界的農民,並肩協助面對糧食危機或氣候變遷等全球性挑戰。」

拜耳總裁Werner Baumann說,「併購孟山都是因為我們深信兩家公司的結合可以幫助處理現今及未來農民和農業所面臨的眾多挑戰。拜耳和孟山都在一起,可以提供客戶所需要的嶄新、創新的解決方案。我們期待交易完成,也會與孟山都密切合作,以確保整合成功。」

根據初步的股東投票表格,約99%的股東投票贊成併購案,股東特別會議是以2016年11月7日的紀錄為基準點,參與會議股東的持股,約代表75%的流通股份。孟山都的股東也同意,可支付或考慮支付受此併購案影響的公司任命主管一定補償的建議。議程提案的最後投票結果,孟山都公司將填具表格8-K,提交美國證券交易委員會(SEC),也可至www.monsanto.com/investors查詢。

這項交易正依慣例與相關法令進行中,包括取得相關主管機關的核准。在孟山都的支持下,拜耳現已提交許多文件,包括美國《哈特-斯科特-羅迪尼反托拉斯改進法》(Hart-Scott-Rodino Act)的相關文件。交易預計會在2017年底完成。
更多有關併購交易提案的資訊,可以上網:www.advancingtogether.com


Bayer: Science For A Better Life
拜耳:科技優化生活
拜耳是在醫療保健的生命科學領域及農業領域擁有核心競爭力的全球性企業。其產品及服務的宗旨為造福人類,並改善人類的生活品質。同時,該集團希望經由創新、成長與高獲利能力創造價值。拜耳致力於永續發展的原則,也致力於身為企業公民的社會責任及道德責任。在2015會計年度,該集團雇用了約11萬7千位員工,營業額為463億歐元。資本支出達到26億歐元、研發支出達到43億歐元。這些數字包括高科技聚合物的業務,2015年10月6日,聚合物業務於以獨立公司Covestro的名義在股市上市。若欲瞭解詳細資訊,請至www.bayer.com

關於孟山都公司
孟山都公司致力於透過不同的農田解決方案來滿足不斷增長的世界人口對於食物和營養的需求。我們生產包括玉米、大豆和棉花等主要農作物以及果蔬種子,幫助全球農民高效率使用水和其它重要自然資源的同時,獲取更好的收成。我們著重於不斷地尋找和開發既保護土壤健康,又可持續發展的農田解決方案,協助農民透過應用農田和氣候數據科學,改善農耕模式保護自然資源,並提供不同的作物保護產品降低害蟲和病害給作物帶來的危害。同時,我們藉由不同項目和合作關係,與農民、科學研究人員、非盈利組織、大學校院和其它機構攜手合作,共同面對諸多嚴峻挑戰。詳情可至官方網站www.monsanto.com,discover.monsanto.com查詢,了解更多關於孟山都公司,永續發展承諾以及2萬多名專注於農業發展的孟山都員工。也可至孟山都推特twitter.com/MonsantoCo和部落格Beyond the Rows® at monsantoblog.com ,或者訂閱RSS Feed了解最新動態。


Cautionary Statements Regarding Forward-Looking Information
Certain statements contained in this communication may constitute “forward-looking statements.” Actual results could differ materially from those projected or forecast in the forward-looking statements. The factors that could cause actual results to differ materially include the following: uncertainties as to the timing of the transaction; the possibility that the parties may be unable to achieve expected synergies and operating efficiencies in the merger within the expected time-frames or at all and to successfully integrate Monsanto’s operations into those of Bayer; such integration may be more difficult, time-consuming or costly than expected; revenues following the transaction may be lower than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) may be greater than expected following the announcement of the transaction; the retention of certain key employees at Monsanto; risks associated with the disruption of management’s attention from ongoing business operations due to the transaction; the conditions to the completion of the transaction may not be satisfied, or the regulatory approvals required for the transaction may not be obtained on the terms expected or on the anticipated schedule; the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the merger; the impact of indebtedness incurred by Bayer in connection with the transaction and the potential impact on the rating of indebtedness of Bayer; the effects of the business combination of Bayer and Monsanto, including the combined company’s future financial condition, operating results, strategy and plans; other factors detailed in Monsanto’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended August 31, 2016 and Monsanto’s other filings with the SEC, which are available at http://www.sec.gov and on Monsanto’s website at www.monsanto.com; and other factors discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. Bayer and Monsanto assume no obligation to update the information in this communication, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.